Travere Therapeutics, Inc. (TVTX)
| Market Cap | 5.92B +180.6% |
| Revenue (ttm) | 591.33M +77.1% |
| Net Income | -43.46M |
| EPS | -0.48 |
| Shares Out | 94.26M |
| PE Ratio | n/a |
| Forward PE | 15.96 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,235,840 |
| Open | 64.89 |
| Previous Close | 64.74 |
| Day's Range | 62.47 - 64.89 |
| 52-Week Range | 22.06 - 68.73 |
| Beta | 1.06 |
| Analysts | Strong Buy |
| Price Target | 74.21 (+18.24%) |
| Earnings Date | Oct 29, 2026 |
About TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urin... [Read more]
Financial Performance
In 2025, Travere Therapeutics's revenue was $490.73 million, an increase of 110.45% compared to the previous year's $233.18 million. Losses were -$25.55 million, -92.06% less than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for TVTX stock is "Strong Buy." The 12-month stock price target is $74.21, which is an increase of 18.24% from the latest price.
News
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, Sep...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on September 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants ...
Travere Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
FILSPARI continues to drive strong growth in both IgA nephropathy and FSGS, supported by robust physician adoption and favorable market dynamics. The pipeline, including pegtibatinase and civorebrutinib, is advancing with significant addressable markets and strategic synergies. Financial strength is underpinned by $489 million in cash and no near-term capital needs.
Travere Therapeutics price target raised to $68 from $49 at Piper Sandler
Piper Sandler raised the firm’s price target on Travere Therapeutics (TVTX) to $68 from $49 as Filspari FSGS launch is off to the races. The firm keeps an Overweight rating…
Travere Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference
The company is driving growth through FILSPARI's strong performance in IgA nephropathy and FSGS, expanding its rare disease pipeline with pegtibatinase and civorebrutinib, and expects further market expansion as diagnosis rates improve and combination therapies become standard. Recent patent progress extends exclusivity, and pivotal trial data for pegtibatinase is anticipated next year.
Travere Therapeutics price target raised to $78 from $68 at Evercore ISI
Evercore ISI raised the firm’s price target on Travere Therapeutics (TVTX) to $78 from $68 and keeps an Outperform rating on the shares.
Travere Therapeutics price target raised to $75 from $61 at Wedbush
Wedbush raised the firm’s price target on Travere Therapeutics (TVTX) to $75 from $61 and keeps an Outperform rating on the shares. Following the Q2 Filsparidriven beat, the firm is…
Travere Therapeutics price target raised to $70 from $62 at Canaccord
Canaccord raised the firm’s price target on Travere Therapeutics (TVTX) to $70 from $62 and keeps a Buy rating on the shares. The firm said in 2Q26 Filspari product sales…
Travere Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: Canaccord Genuity's 46th ...
Travere Therapeutics price target raised to $68 from $60 at Evercore ISI
Evercore ISI raised the firm’s price target on Travere Therapeutics (TVTX) to $68 from $60 and keeps an Outperform rating on the shares.
Travere Therapeutics price target raised to $75 from $60 at TD Cowen
TD Cowen raised the firm’s price target on Travere Therapeutics (TVTX) to $75 from $60 and keeps a Buy rating on the shares. The firm said its Q2 results were…
Travere Therapeutics price target raised to $75 from $65 at Guggenheim
Guggenheim raised the firm’s price target on Travere Therapeutics (TVTX) to $75 from $65 and keeps a Buy rating on the shares. The firm is updating its model following the…
Travere Therapeutics price target raised to $62 from $43 at Stifel
Stifel raised the firm’s price target on Travere Therapeutics (TVTX) to $62 from $43 and keeps a Hold rating on the shares.
Travere Therapeutics price target raised to $85 from $70 at Citi
Citi raised the firm’s price target on Travere Therapeutics (TVTX) to $85 from $70 and keeps a Buy rating on the shares. The firm says the company reported better than…
Travere Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw record FILSPARI revenue and strong launches in both IgA nephropathy and FSGS, with over 2,000 new patient starts and 96% year-over-year sales growth. The pipeline advanced with pegtibatinase and civorebrutinib, and the company ended the quarter with $489 million in cash.
Travere Therapeutics Earnings release: Q2 2026
Travere Therapeutics released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Travere Therapeutics Slides: Q2 2026
Travere Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Travere Therapeutics Quarterly report: Q2 2026
Travere Therapeutics has published its Q2 2026 quarterly earnings report on August 4, 2026.
Travere Therapeutics reports Q2 adjusted EPS (10c), consensus (14c)
Reports Q2 revenue $169.58M, consensus $159.59M. “With an exceptional second quarter, Travere has entered a new chapter of near- and long-term growth,” said Eric Dube, Ph.D., president and chief execu...
Travere Therapeutics Reports Second Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its second quarter 2026 financial results and provided a corporate update. “With an exceptional second quarter, Tra...
Travere Therapeutics price target raised to $62 from $56 at Canaccord
Canaccord raised the firm’s price target on Travere Therapeutics (TVTX) to $62 from $56 and keeps a Buy rating on the shares. The firm updated its model ahead of Q2…
Travere Therapeutics to Report Second Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. finan...
Travere Therapeutics price target raised to $64 from $59 at BofA
BofA raised the firm’s price target on Travere Therapeutics (TVTX) to $64 from $59 and keeps a Buy rating on the shares. The firm, which is updating its model for…
Travere Therapeutics price target raised to $65 from $56 at Guggenheim
Guggenheim analyst Vamil Divan raised the firm’s price target on Travere Therapeutics (TVTX) to $65 from $56 and keeps a Buy rating on the shares, which remain the analyst’s “Best…
Travere Therapeutics price target raised to $61 from $55 at Wedbush
Wedbush analyst Laura Chico raised the firm’s price target on Travere Therapeutics (TVTX) to $61 from $55 and keeps an Outperform rating on the shares. Following discussions with Travere’s management…